SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy

Condition:   Myelodysplastic Syndromes Intervention:   Drug: SX-682 Sponsors:   Syntrix Biosystems, Inc.;   H. Lee Moffitt Cancer Center and Research Institute;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials